Olmesartán/Amlodipino/Hidroclorotiazida Cinfamed (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/Hydrochlorothiazide is a combination antihypertensive used to manage elevated blood pressure across several clinical scenarios.

• Essential hypertension: lowers systolic and diastolic pressure in adults.
• Resistant hypertension: provides additional control when other agents are insufficient.
• Hypertension with peripheral edema: amlodipine component helps counteract fluid retention while maintaining blood pressure reduction.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. Hydrochlorothiazide acts on the distal convoluted tubule to promote sodium and water excretion, reducing plasma volume. The three mechanisms together produce additive blood‑pressure lowering effects.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: feeling light‑headed, especially after standing.
• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Flushing: transient warmth and redness of the skin.
• Fatigue: general tiredness or lack of energy.
• Increased urination: due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Electrolyte imbalance: especially low potassium or sodium levels.
• Acute renal impairment: sudden decline in kidney function.
• Angioedema: swelling of face, lips, tongue, or throat.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Patients should be evaluated for specific risk factors before initiating therapy.

• Blood pressure monitoring: ensure adequate control without excessive drop.
• Renal function assessment: check creatinine and eGFR regularly.
• Electrolyte surveillance: monitor potassium and sodium levels.
• Pregnancy avoidance: not recommended during pregnancy due to fetal risk.
• Hepatic impairment caution: dose adjustment may be required.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine/HCTZ can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• ACE inhibitors or ARBs with aliskiren in diabetic patients: increased renal adverse events.
• Lithium: heightened lithium toxicity.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• Cyclosporine: additive nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive hypotensive effect.
• Other antihypertensives: cumulative blood‑pressure lowering.
• Antidiabetic agents: possible need for dose adjustment.
• Corticosteroids: may reduce diuretic efficacy.
• Alcohol: can enhance hypotensive response.